Suzanne M. McCluskey

Dr. Suzanne M. McCluskey


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in AIDS
Verified
Journal Article
Open access
SMSuzanne M. McCluskey
Suzanne M. McCluskey
TPToby Pepperrell
Toby Pepperrell
AHAndrew Hill
Andrew Hill
WVWillem D.F. Venter
Willem D.F. Venter
RGRavindra K. Gupta
Ravindra K. Gupta
MSMark J. Siedner
Mark J. Siedner
Dolutegravir (DTG) is now a component of preferred first-line antiretroviral therapy (ART) worldwide. ADVANCE and NAMSAL were two landmark clinical trials conducted exclusively in sub-Saharan Africa, which studied the effectiveness of DTG-based first-line regimens for ART-naive individuals. In this review, we examine the data from these studies to consider the contributions of adherence and HIV drug resistance to treatment failure on DTG-based ART, as compared with efavirenz (EFV)-based ART, which has a lower genetic barrier to resistance. We also discuss the implications of virologic failure on DTG and consolidate currently available data to conclude with recommendations for virologic monitoring on DTG-based ART.

1 September 2019 in Infectious Disease Clinics of North America
Verified
Journal Article
Closed access
SMSuzanne M. McCluskey
Suzanne M. McCluskey
MSMark J. Siedner
Mark J. Siedner
VMVincent C. Marconi
Vincent C. Marconi

4 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
CCCarolyn Chu
Carolyn Chu
KTKaiming Tao
Kaiming Tao
VKVinie Kouamou
Vinie Kouamou
AAAva Avalos
Ava Avalos
JSJake Scott
Jake Scott
Robert W ShaferRobert W Shafer
Robert W Shafer
Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART. Methods: We performed a PubMed search using the term “Dolutegravir”, last updated 18 December 2023, to estimate the prevalence of VF with emergent INSTI DRMs in people living with HIV (PLWH) without previous VF on an INSTI who received DTG-containing ART. Results: Of 2131 retrieved records, 43 clinical trials, 39 cohorts, and 6 cross-sectional studies provided data across 6 clinical scenarios based on ART history, virological status, and co-administered ARVs: (1) ART-naïve PLWH receiving DTG plus two NRTIs; (2) ART-naïve PLWH receiving DTG plus lamivudine; (3) ART-experienced PLWH with VF on a previous regimen receiving DTG plus two NRTIs; (4) ART-experienced PLWH with virological suppression receiving DTG plus two NRTIs; (5) ART-experienced PLWH with virological suppression receiving DTG and a second ARV; and (6) ART-experienced PLWH with virological suppression receiving DTG monotherapy. The median proportion of PLWH in clinical trials with emergent INSTI DRMs was 1.5% for scenario 3 and 3.4% for scenario 6. In the remaining four trial scenarios, VF prevalence with emergent INSTI DRMs was ≤0.1%. Data from cohort studies minimally influenced prevalence estimates from clinical trials, whereas cross-sectional studies yielded prevalence data lacking denominator details. Conclusions: In clinical trials, the prevalence of VF with emergent INSTI DRMs in PLWH receiving DTG-containing regimens has been low. Novel approaches are required to assess VF prevalence with emergent INSTI DRMs in PLWH receiving DTG in real-world settings.

26 December 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
ANAndrea Perez Navarro
Andrea Perez Navarro
CNCameron T Nutt
Cameron T Nutt
MSMark J Siedner
Mark J Siedner
SMSuzanne M. McCluskey
Suzanne M. McCluskey
AHAndrew Hill
Andrew Hill
Background: The long-acting injectable regimen of cabotegravir plus rilpivirine (CAB/RPV) emerged as an alternative to oral standard-of-care integrase strand transfer inhibitor (INSTI)–based regimens for individuals with adherence challenges or preference for reduced dosing schedules. Although oral INSTI regimens have a high barrier to emergent resistance, less is known about the potency and durability of CAB/RPV. Methods: We reviewed clinical trial registries, PubMed, EMBASE, and conference abstract databases to identify reports of CAB/RPV for HIV therapy. We abstracted data on virologic failure (VF) and treatment-emergent INSTI resistance at 48 weeks (range: 24–52). We used single-proportion meta-analysis to summarize outcomes in 3 populations: antiretroviral therapy (ART)–naive individuals initiating CAB/RPV following suppression on oral ART, ART-experienced individuals switched to CAB/RPV with virologic suppression, and ART-experienced individuals switched to CAB/RPV with detectable viremia. Cochrane's RoB 2.0 and ROBINS-1 tools assessed risk of bias. Results: Thirty-three studies (N = 9224) reported VF prevalence. Nineteen studies (N = 5662) reported resistance data. VF prevalence was 1% (95% CI: 1%–3%) in induction-maintenance studies, 1% (1%–2%) in switch-suppressed studies, and 5% (3%–10%) in switch-viremic studies. INSTI resistance prevalence among successfully genotyped participants at failure was 71% (25%–95%), 61% (44%–75%), and 41% (20%–65%) respectively. Dolutegravir cross-resistance was common (64% of those with emergent resistance). Conclusions: Although VF rates with CAB/RPV were low, INSTI resistance emerged in approximately 40%–70% of individuals experiencing VF. These rates are significantly higher than those for oral INSTI-based regimens. Both individual-level and broader resistance surveillance may be warranted in populations with expanding CAB/RPV use. Clinical Trials Registration. PROSPERO registration CRD42024543919.

16 February 2023 in AIDS
Verified
Journal Article
Closed access
SMSuzanne M. McCluskey
Suzanne M. McCluskey
KGKatya Govender
Katya Govender
JAJohn Adamson
John Adamson
MGMonica Gandhi
Monica Gandhi
MSMatthew A. Spinelli
Matthew A. Spinelli
MSMark J. Siedner
Mark J. Siedner
Objective: We sought to evaluate the utility of a point-of-care (POC) urine tenofovir (TFV) assay, developed to objectively assess adherence, to predict HIV drug resistance (HIVDR) in people failing first-line antiretroviral therapy (ART). Design: We retrospectively analyzed TFV levels as a biomarker of adherence in urine specimens collected during a clinical trial that enrolled adults with virologic failure on first-line ART in Uganda and South Africa. Methods: Urine specimens were analyzed from participants on TFV-containing regimens who had a viral load >1000 copies/ml and paired genotypic resistance test (GRT) results. We assessed recent ART TFV adherence with a qualitative POC lateral flow urine assay with a cut-off value of 1500 ng/ml. We then calculated performance characteristics of the POC urine TFV assay to predict HIVDR, defined as intermediate or high-level resistance to any component of the current ART regimen. Results: Urine specimens with paired plasma GRT results were available from 283 participants. The most common ART regimen during study conduct was emtricitabine, tenofovir disoproxil fumarate, and efavirenz. The overall prevalence of HIVDR was 86% (n = 243/283). Of those with TFV detected on the POC assay, 91% (n = 204/224) had HIVDR, vs. only 66% (n = 39/59) among those with no TFV detected (P-value < 0.001). Positive and negative predictive values of the assay to predict HIVDR were 91% and 34%, respectively. Conclusions: In populations with a high prevalence of HIVDR, the POC urine TFV assay can provide a low-cost, rapid method to guide requirements for confirmatory resistance testing and inform the need for regimen change.

1 October 2017 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
SMSuzanne M. McCluskey
Suzanne M. McCluskey
YBYap Ii Boum
Yap Ii Boum
NMNicholas Msc Musinguzi
Nicholas Msc Musinguzi
JHJessica E. Haberer
Jessica E. Haberer
JMJeffrey N. Martin
Jeffrey N. Martin
MSMark J. Siedner
Mark J. Siedner
Background: The World Health Organization defines HIV virologic failure as 2 consecutive viral loads >1000 copies/mL, measured 3–6 months apart, with interval adherence support. We sought to empirically evaluate these guidelines using data from an observational cohort. Setting: The Uganda AIDS Rural Treatment Outcomes study observed adults with HIV in southwestern Uganda from the time of antiretroviral therapy (ART) initiation and monitored adherence with electronic pill bottles. Methods: We included participants on ART with a detectable HIV RNA viral load and who remained on the same regimen until the subsequent measurement. We fit logistic regression models with viral resuppression as the outcome of interest and both initial viral load level and average adherence as predictors of interest. Results: We analyzed 139 events. Median ART duration was 0.92 years, and 100% were on a nonnucleoside reverse-transcriptase inhibitor–based regimen. Viral resuppression occurred in 88% of those with initial HIV RNA 1000 copies/mL (P <0.001). Adherence after detectable viremia predicted viral resuppression for those with HIV RNA 1000 copies/mL (P = 0.894; interaction term P = 0.077). Conclusions: Among patients on ART with detectable HIV RNA >1000 copies/mL who remain on the same regimen, only 42% resuppressed at next measurement, and there was no association between interval adherence and viral resuppression. These data support consideration of resistance testing to help guide management of virologic failure in resource-limited settings.